ReviewFrontiers in medicine2025
Advances in research on the role of gut microbiota in the pathogenesis and precision management of gallstone disease.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07439640 (Clinical Experimental Study on the Impact of PEG Laxatives for Intestinal Preparation on Gut Microbiota in Patients Undergoing Cholecystectomy), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Experimental Study on the Impact of PEG Laxatives for Intestinal Preparation on Gut Microbiota in Patients Undergoing Cholecystectomy
Who cites it
4 citing papers in PubMed.
- Denture use is associated with a higher risk of cholelithiasis: a prospective cohort study.BMC oral health · 2026Article
- Restructuring the gut microbiota in obesity: molecular mechanisms linking dysbiosis to systemic inflammation and therapeutic opportunities.Frontiers in physiology · 2026Review
- Gut microbiota-derived short-chain fatty acids in gallstones: mechanisms and intervention strategies.Frontiers in microbiology · 2026Review
- Research progress on the role of microbiota in the pathogenesis of gallstone disease.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallstone disease remains a prevalent global gastrointestinal condition with a rising incidence, posing substantial challenges to healthcare systems and public health initiatives. Advances in multi-omics and sequencing technologies have illuminated the pivotal role of gut microbiota in its pathogenesis, progression, and management. This article reviews the disrupted microbiota profiles observed in patients with gallstone disease and their connection to the metabolic pathways involved in gallstone formation, particularly focusing on cholesterol metabolism, bile acid dynamics, and inflammatory pathways. It also discusses the enduring impacts of cholecystectomy on gut microbial functions and their metabolic implications. Novel strategies targeting gut microbiota, including probiotics, microbial metabolite supplementation, dietary adjustments, integrative medicine, and emerging microbial therapies, present promising avenues for precise treatment. Furthermore, this review underscores the value of future research into multi-omics integration, microbiome engineering, and global collaborations, advocating for interdisciplinary and personalized approaches to gallstone management. However, unresolved challenges, such as ensuring stable colonization of functional microbiota, refining tailored therapeutic strategies, and assessing long-term outcomes, warrant further investigation. This work aims to provide a comprehensive resource for understanding gallstone disease within a microecological framework, supporting the development of precision medicine-based prevention and treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.